Shares ofGoPro (NASDAQ:GPRO) sank to fresh all-time lows on Monday, following an analyst downgrade (via Tech Trader Daily). Goldman Sachs analyst Simona Jankowski dropped her rating on GoPro from neutral to sell, while simultaneously slashing her price target down to a mere $6, or about 30% lower
Penn West Petroleum Ltd. (NYSE:PWE) has been to the financial cliff and back again. The achievements of the last two years are probably top 1% in many areas. There was a little trepidation as the latest announcement saw more changes in senior management. For many shareholders, those senior manage
General Electric Co. (NYSE: GE) shares managed to post a gain of 3.3% last week, but it wasn’t enough for the industrial giant to move out of its rank as the worst-performing Dow Jones industrial average stock for the year to date. Even with the weekly gain, shares are down 22.7% so far in 2018.
The second-worst Dow stock so far this year is Procter & Gamble Co. (NYSE: PG), which....More>>>
If you’re looking for tips on how to make money withpenny stocks today, we have one tip that can help you find the safest companies to invest in.
Investing in penny stocks is popular for one big reason: The shares are inexpensive, usually below $5, so you can quickly make triple-digit profits. Biotech penny stock Oncobiologics Inc. (Nasdaq: ONS) soared from $0.87 to $1.89 between....More>>>
We have been fans of DNB (OTCPK:DNHBY) (OTCPK:DNBHF) for quite a long time now. It is the largest financial services group in Norway, and, more importantly, one of the safest banks in the world. A little less than a year ago, we said that DNB was offering a ‘once-in-a-lifetime’ buying opportunity. Our high-conviction contrarian call was based on the fact that DNB was trading at a very....More>>>
(Editor’s note: There is much greater liquidity on the Frankfurt Stock Exchange under ticker Z01).
The Elevator Pitch
Zooplus (OTC:ZOPLY) (OTC:ZLPSF) is the leading online retailer of pet food and supplies in Europe. Generally, in a commoditized market such as selling pet food, the lowest cost provider with the best customer service has the “right to win”. We believe....More>>>
24/7 Wall St. has put together a preview of a few major companies scheduled to report their quarterly results this coming week. The third-quarter earnings reporting season has just kicked off and the broad markets are near all-time highs. They could look to keep pushing higher with the recent rally in the tech sector, and a strong earnings showing from these stocks could to keep this rally going.
The stock market’s post-election euphoria has subsided a bit. But the Dow is still trading above 19,000 — which means it is less than 5% away from topping the much sexier psychological milestone of 20,000 for the first time ever.
Will the Dow get past 20K anytime soon? Or will the Trump bump on Wall Street be replaced by the Trump slump?
Shares of Rogers Corp. (NYSE:ROG) gained 19.9% in April 2017, according to data from S&P Global Market Intelligence.
The company reported first-quarter results on April 26, sending share prices nearly 12% higher the next day. Rogers saw 27% year-over-year sales growth and 79% higher earnings, leaving analyst estimates far behind in both cases.
Athenex Inc (NASDAQ:ATNX) shares saw an uptick in trading volume on Friday . 4,670,100 shares traded hands during trading, an increase of 1,213% from the previous session’s volume of 355,816 shares.The stock last traded at $19.05 and had previously closed at $18.62.
Media coverage about Kopin (NASDAQ:KOPN) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of ne
Wall Street brokerages predict that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will report ($0.15) earnings per share for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Neurocrine Biosciences’ earnings, with the highest EPS estimate coming
Oppenheimer set a $120.00 target price on Neurocrine Biosciences (NASDAQ:NBIX) in a report published on Monday morning. The brokerage currently has a buy rating on the stock. Oppenheimer also issued estimates for Neurocrine Biosciences’ FY2021 earnings at $7.03 EPS and FY2022 earnings at